Original Article

You have free access to this content

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma

  1. Jeffrey S. Weber MD, PhD1,†,*,
  2. Hassan Zarour MD2,
  3. Bruce Redman MD3,
  4. Uwe Trefzer MD4,
  5. Steven O'Day MD5,
  6. Alfons J. M. van den Eertwegh MD6,
  7. Ernest Marshall MD7,8,
  8. Stefan Wagner MD9

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24473

Issue

Cancer

Cancer

Volume 115, Issue 17, pages 3944–3954, 1 September 2009

Additional Information

How to Cite

Weber, J. S., Zarour, H., Redman, B., Trefzer, U., O'Day, S., van den Eertwegh, A. J. M., Marshall, E. and Wagner, S. (2009), Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer, 115: 3944–3954. doi: 10.1002/cncr.24473

Author Information

  1. 1

    Moffitt Cancer Center, Tampa, Florida

  2. 2

    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

  3. 3

    University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  4. 4

    Humboldt University, Berlin, Germany

  5. 5

    The Angeles Clinic Research Institute, Los Angeles, California

  6. 6

    University of Graz, Graz, Austria

  7. 7

    VU Medical Center, Amsterdam, the Netherlands

  8. 8

    University of Kentucky Medical Center, Lexington, Kentucky

  9. 9

    University of Vienna, Vienna, Austria

  1. †

    Fax: (813) 745-4384

*Department of Oncologic Sciences, Moffitt Cancer Center, 12902 Magnolia Drive SRB-2, Tampa, FL 33612

Publication History

  1. Issue published online: 20 AUG 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 15 DEC 2008
  4. Manuscript Revised: 4 DEC 2008
  5. Manuscript Received: 3 SEP 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (242K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Julia K. Tietze, Gail D. Sckisel, Hui-Hua Hsiao, William J. Murphy, Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?, International Reviews of Immunology, 2011, 30, 5-6, 238

    CrossRef

  2. 2
    Udo Holtick, Nela Klein-Gonzalez, Michael S von Bergwelt-Baildon, Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?, Immunotherapy, 2011, 3, 3, 301

    CrossRef

  3. 3
    Amy Gillgrass, Ali Ashkar, Stimulating natural killer cells to protect against cancer: recent developments, Expert Review of Clinical Immunology, 2011, 7, 3, 367

    CrossRef

  4. 4
    Aisling Dunne, Neil A Marshall, Kingston HG Mills, TLR based therapeutics, Current Opinion in Pharmacology, 2011, 11, 4, 404

    CrossRef

  5. 5
    Udo Holtick, Max E Scheulen, Michael S von Bergwelt-Baildon, Martin R Weihrauch, Toll-like receptor 9 agonists as cancer therapeutics, Expert Opinion on Investigational Drugs, 2011, 20, 3, 361

    CrossRef

  6. 6
    Y. Lin, M. P. Gustafson, P. A. Bulur, D. A. Gastineau, T. E. Witzig, A. B. Dietz, Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma, Blood, 2010, 117, 3, 872

    CrossRef

  7. 7
    Christian Busch, Jürgen Geisler, Johan R. Lillehaug, Per Eystein Lønning, MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC, European Journal of Cancer, 2010, 46, 11, 2127

    CrossRef

  8. You have free access to this content8
    Makoto Iwahashi, Masahiro Katsuda, Mikihito Nakamori, Masaki Nakamura, Teiji Naka, Toshiyasu Ojima, Takeshi Iida, Hiroki Yamaue, Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma, Cancer Science, 2010, 101, 12
    Direct Link:
  9. 9
    Ami Sabharwal, Mark Middleton, Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions, 2010,

    CrossRef

View Full Article (HTML) Get PDF (242K)